Immunotherapy improves remission for relapsed, refractory leukemia: Clinical trial

A single infusion of chimeric antigen receptor T-cell (CAR-T) therapy induced complete response or remission in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a recent clinical trial published in The Lancet.

Leave A Comment

Your email address will not be published. Required fields are marked *